Research programme: VEGF inhibitors - Opthea
Alternative Names: VGX-200; VGX-200 seriesLatest Information Update: 07 Jun 2023
At a glance
- Originator Vegenics
- Developer Circadian Technologies; Opthea
- Class Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Eye disorders
Most Recent Events
- 31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Australia (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Eye-disorders in Australia (Ophthalmic)